The latter hypothesis is based on the studies from Karadagi et al. [9] wherein an increase in SerpinA1 protein by augmentation therapy demonstrated a decrease in the PIZZ form in AATD patient PBMC. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.